top of page
Search
Oregon’s Psilocybin Program: First Data Reveals Trends and Challenges
The nation’s first regulated psilocybin market shows promise but faces hurdles in accessibility and cost. In 2020, Oregon became the...
Jul 17
Compass Pathways Hits Milestone in Psychedelic Drug Development with Phase 3 Psilocybin Readout for 250+ Patients
Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...
Jun 23
Psilocybin for Depression: A Closer Look at the Evidence
With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...
May 19
Microdosing Psilocybin for Women’s Health: Endometriosis, PMDD & Menopause | Mabel
Mabel: Microdosing Psilocybin for Women’s Health
Apr 6
Could Psychedelic Therapies Offer New Hope for Alzheimer's Disease?
Alzheimer’s Disease (AD) is a pressing global challenge, with cases expected to triple globally, affecting around 152 million people by...
Mar 29
bottom of page